Servier Acquires Edgewise for $2.65B Muscular Dystrophy

France-based Servier will acquire sevasemten and Edgewise Therapeutics' muscular dystrophy business for USD 1.55 billion in upfront cash plus up to USD 1.1 billion in regulatory and commercial milestones, bringing aggregate potential consideration to USD 2.65 billion. The deal allows Servier to establish an immediate platform in Becker and Duchenne muscular dystrophy while Edgewise Therapeutics (Nasdaq: EWTX), headquartered in Boulder, Colorado, refocuses entirely on its cardiac sarcomere pipeline.

Under the definitive agreement, Servier acquires all global rights to sevasemten, encompassing related intellectual property, regulatory filings, clinical data, and key agreements, with no disclosed territorial carve-outs. Relevant Edgewise employees supporting the muscular dystrophy business will receive comparable offers at Servier to preserve development and commercial continuity. The USD 1.1 billion in contingent payments is described collectively as regulatory and commercial milestones, with no individual tranche triggers publicly disclosed. The transaction, unanimously approved by both boards, is subject to HSR antitrust clearance and is expected to close in Q3 2026. Edgewise stated that upfront proceeds, combined with existing cash, will fully fund the progress of its cardiovascular candidate EDG-7500.

Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to selectively limit exaggerated muscle damage arising from absent or dysfunctional dystrophin. In the MESA open-label extension study, participants maintained stable North Star Ambulatory Assessment scores over more than three years of treatment, contrasting with the functional decline expected from Becker natural history data, and no discontinuations or dose reductions due to adverse events were reported. The fully enrolled GRAND CANYON pivotal cohort in Becker — 175 participants, powered at greater than 98% for a statistically significant difference versus placebo — has top-line data expected in Q4 2026, a readout that will now sit on Servier's timeline. Sevasemten holds FDA Orphan Drug and Fast Track designations for both Becker and Duchenne, Rare Pediatric Disease Designation for Duchenne, and EMA Orphan Drug Designations for both indications; if approved in Becker, it would be the first therapy indicated for that condition.

The transaction is the second major acquisition Servier has executed at the USD 2–3 billion scale within a short window. The company previously acquired Day One Biopharmaceuticals and its pediatric oncology asset Ojemda (tovorafenib) for approximately USD 2.5 billion, a deal that similarly reflected Servier's stated 2030 ambition to become a significant player in precision therapeutics for underserved patient populations. The sevasemten transaction extends that strategy into neuromuscular disease, giving Servier a late-stage rare disease asset with a near-term pivotal catalyst, potentially shortening the path to commercialization relative to earlier-stage licensing deals.

For Edgewise, the partial asset sale — rather than a full company acquisition — is a deliberate structural choice that preserves shareholder exposure to the cardiovascular pipeline. Post-close, the company will advance EDG-7500, a cardiac sarcomere modulator in Phase II development for symptomatic hypertrophic cardiomyopathy, with 12-week data from Part D of the CIRRUS-HCM trial expected in Q2 2026 and Phase III initiation targeted for Q4 2026. EDG-15400, a second cardiac sarcomere modulator targeting heart failure with preserved ejection fraction, is on track to enter Phase II, and EDG-003 addresses an undisclosed cardiovascular target. The transaction's upfront proceeds effectively de-risk the EDG-7500 program's path to a potential approval decision, removing the financing overhang that typically constrains single-asset cardiovascular biotechs at the Phase II-to-III transition.

Spot something wrong? Report an issue with this article

The AllSci Brief